Opko Health (OPK) Stock Price Down 5.1%

Opko Health Inc. (NASDAQ:OPK) was down 5.1% during trading on Thursday . The company traded as low as $2.40 and last traded at $2.42. Approximately 5,598,653 shares changed hands during mid-day trading, an increase of 2% from the average daily volume of 5,473,209 shares. The stock had previously closed at $2.55.

A number of equities research analysts recently commented on OPK shares. Zacks Investment Research raised shares of Opko Health from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Friday, November 30th. ValuEngine raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Barrington Research reaffirmed a “buy” rating and issued a $5.00 price target on shares of Opko Health in a report on Thursday, February 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $9.67.

The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.96 and a current ratio of 1.10. The firm has a market capitalization of $1.57 billion, a P/E ratio of -9.68 and a beta of 1.88.



In other Opko Health news, Vice Chairman Jane Ph D. Hsiao bought 10,000 shares of the stock in a transaction on Thursday, January 31st. The shares were acquired at an average price of $7.96 per share, with a total value of $79,600.00. Following the acquisition, the insider now directly owns 24,455,147 shares of the company’s stock, valued at approximately $194,662,970.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Phillip Md Et Al Frost bought 100,000 shares of the stock in a transaction on Friday, December 28th. The shares were acquired at an average cost of $3.13 per share, for a total transaction of $313,000.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $9,605,816.63. The disclosure for this purchase can be found here. Insiders purchased a total of 908,000 shares of company stock worth $2,749,080 in the last ninety days. 42.74% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of OPK. Diversified Trust Co bought a new stake in Opko Health during the 4th quarter valued at $30,000. FDx Advisors Inc. bought a new stake in Opko Health during the 4th quarter valued at $33,000. Douglas Lane & Associates LLC bought a new stake in Opko Health during the 4th quarter valued at $42,000. Kovack Advisors Inc. bought a new stake in Opko Health during the 4th quarter valued at $48,000. Finally, Two Sigma Advisers LP bought a new stake in Opko Health during the 4th quarter valued at $49,000. 23.73% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece was reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://dakotafinancialnews.com/2019/03/15/opko-health-opk-stock-price-down-5-1.html.

Opko Health Company Profile (NASDAQ:OPK)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Read More: How to interpret a stock’s beta number

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply